The board of directors of Amgen (NASDAQ:AMGN) declared on Wednesday its dividend of USD1.76 per share for the Q2 2021.
This dividend is due on 8 June 2021 to all stockholders of record as of the close of business as of 17 May 2021.
According to the company, it is engaged in discovering, developing, manufacturing and delivering innovative human therapeutics via advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
A biotechnology pioneer, the company has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva